Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups. Three companies comprise the inaugural funding cycle of Illumina Accelerator Cambridge, UK and four companies will join as part of the 11th funding cycle in the San Francisco Bay Area. Due to lockdowns and travel restrictions during t

Illumina Accelerator Welcomes First Global Cohort of Genomics Startups

With this acquisition, the cloud capability of BlueBee's platform will help Illumina (ILMN) to lower the cost of storing, sharing and managing the company's huge volumes of genomic data.

Illumina Takes Over BlueBee, Fortifies NGS Data Processing

Gilead Sciences

GILD vs. ILMN: Which Stock Is the Better Value Option?

COVIDSeq is the first COVID-19 diagnostic test based on gene sequencing to receive a green light from the regulator.

Illumina Wins FDA Authorization for Sequencing-Based COVID-19 Test

Illumina's (ILMN) NGS-based test for the detection of the SARS-CoV-2 receives the FDA's EUA to enable high-volume screening.

Illumina's (ILMN) NGS Test for Detecting Coronavirus Gets EUA

Vir Biotechnology

These three biotechs are hotly traded for good reason.

3 Biotech Quick Picks to Invest $5,000 This Week

Illumina’s revenue woes may not be over as the coronavirus disruption continues, but the future still looks bright for this genome sequencing leader.

Could Illumina Be a Millionaire-Maker Stock?

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock?

Why Is Illumina (ILMN) Up 13.8% Since Last Earnings Report?

BOSTON, May 28, 2020 /PRNewswire/ -- Today, Ginkgo Bioworks is announcing a $70MM investment from Illumina (Nasdaq: ILMN) and existing Ginkgo investors, General Atlantic and Viking Global Investors. This will enable Ginkgo to build the infrastructure that could enable rapid epidemic...

Ginkgo Bioworks to Build Infrastructure for Rapid Epidemic Response with $70MM Investment

Vertex Pharmaceuticals

VRTX vs. ILMN: Which Stock Is the Better Value Option?

VRTX vs. ILMN: Which Stock Should Value Investors Buy Now?

Natera

SAN CARLOS, Calif. and SAN DIEGO, May 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, and Illumina Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing platforms, today announced that they have settled their patent...

Natera and Illumina Settle Patent Dispute

Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.

Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View

Illumina Inc. (ILMN) CEO Francis deSouza on Q1 2020 Results - Earnings Call Transcript

Adaptive Biotechnologies

One company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.

Better Buy: Illumina vs. Adaptive Biotechnologies

Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Illumina (ILMN) Might Surprise This Earnings Season

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Illumina (ILMN) Q1 Earnings Expected to Decline

The biotech expects a tough second quarter, but maintains that its long-term prospects are solid.

Illumina Reports Preliminary First-Quarter Revenue, Withdraws Full-Year Guidance

Investors remain optimistic on Illumina's (ILMN) strong preliminary revenue results for first-quarter 2020.

Illumina (ILMN) Posts Q1 Preliminary Results, Withdraws View

Illumina Inc. ILMN, +2.91% , which specializes in genetic testing and DNA sequencing, said Tuesday afternoon that its first-quarter revenue will beat its own projections and estimates that have declined in the wake of the COVID-19 pandemic.

DNA-sequencing specialist Illumina says sales will beat diminished expectations

Exelixis

EXEL vs. ILMN: Which Stock Is the Better Value Option?

EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?

Illumina shines as investors flock to shares less vulnerable to coronavirus disruptions.

Why Illumina Shares Rose 2.8% in March

This gene-sequencing pioneer hasn't been immune to the coronavirus' effects. But do Illumina's long-term prospects outweigh any short-term pain?

Should You Buy Illumina Stock During the Coronavirus Bear Market?

Boston Scientific

Revenue prospects after the coronavirus outbreak make these companies a good buy today.

2 Medical Device Companies Trading at Bargain Prices

Illumina (ILMN) closed the most recent trading day at $237.76, moving -1.75% from the previous trading session.

News for Illumina Stock (ILMN)